RESUMEN
This randomized placebo-controlled trial tested the efficacy of oral naltrexone with or without fluoxetine for preventing relapse to heroin addiction and for reducing HIV risk, psychiatric symptoms, and outcome. All patients received drug counseling with parental or significant-other involvement to encourage adherence. Patients totaling 414 were approached, 343 gave informed consent, and 280 were randomized (mean age, 23.6 +/- 0.4 years). At 6 months, two to three times as many naltrexone patients as naltrexone placebo patients remained in treatment and had not relapsed, odds ratio (OR) = 3.5 (1.96-6.12), p < .0001. Overall, adding fluoxetine did not improve outcomes, OR = 1.35 (0.68-2.66), p = .49; however, women receiving naltrexone and fluoxetine showed a trend toward a statistically significant advantage when compared to women receiving naltrexone and fluoxetine placebo, OR = 2.4 (0.88-6.59), p = .08. HIV risk, psychiatric symptoms, and overall adjustment were markedly improved among all patients who remained on treatment and did not relapse, regardless of group assignment. More widespread use of naltrexone could be an important addition to addiction treatment and HIV prevention in Russia.
Asunto(s)
Antidepresivos de Segunda Generación/uso terapéutico , Fluoxetina/uso terapéutico , Dependencia de Heroína/rehabilitación , Heroína/efectos adversos , Naltrexona/uso terapéutico , Antagonistas de Narcóticos/uso terapéutico , Abuso de Sustancias por Vía Intravenosa/rehabilitación , Síndrome de Abstinencia a Sustancias/rehabilitación , Adulto , Antidepresivos de Segunda Generación/efectos adversos , Terapia Combinada , Método Doble Ciego , Quimioterapia Combinada , Femenino , Fluoxetina/efectos adversos , Infecciones por VIH/prevención & control , Humanos , Masculino , Naltrexona/efectos adversos , Antagonistas de Narcóticos/efectos adversos , Psicoterapia , Federación de Rusia , Prevención Secundaria , Síndrome de Abstinencia a Sustancias/diagnósticoRESUMEN
Naltrexone may be more effective for treating opioid (heroin) dependence in Russia than in the U.S. because patients are mostly young and living with their parents, who can control medication compliance. In this pilot study we randomized 52 consenting patients who completed detoxification in St. Petersburg to a double blind, 6-month course of biweekly drug counseling and naltrexone, or counseling and placebo naltrexone. Significant differences in retention and relapse favoring naltrexone were seen beginning at 1 month and continuing throughout the study. At the end of 6 months, 12 of the 27 naltrexone patients (44.4%) remained in treatment and had not relapsed as compared to 4 of 25 placebo patients (16%; p<0.05). Since heroin dependence is the main way HIV is being spread in Russia, naltrexone is likely to improve treatment outcome and help reduce the spread of HIV if it can be made more widely available.
